JP2010539241A5 - - Google Patents

Download PDF

Info

Publication number
JP2010539241A5
JP2010539241A5 JP2010525943A JP2010525943A JP2010539241A5 JP 2010539241 A5 JP2010539241 A5 JP 2010539241A5 JP 2010525943 A JP2010525943 A JP 2010525943A JP 2010525943 A JP2010525943 A JP 2010525943A JP 2010539241 A5 JP2010539241 A5 JP 2010539241A5
Authority
JP
Japan
Prior art keywords
group
inhibitor
clemizole
compounds
virus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010525943A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010539241A (ja
JP5715820B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/076806 external-priority patent/WO2009039248A2/en
Publication of JP2010539241A publication Critical patent/JP2010539241A/ja
Publication of JP2010539241A5 publication Critical patent/JP2010539241A5/ja
Application granted granted Critical
Publication of JP5715820B2 publication Critical patent/JP5715820B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010525943A 2007-09-18 2008-09-18 フラビウイルス科ファミリーのウイルスへの感染を治療する方法ならびに、フラビウイルス科ファミリーのウイルスへの感染を治療するための組成物 Expired - Fee Related JP5715820B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US97330907P 2007-09-18 2007-09-18
US60/973,309 2007-09-18
US8875908P 2008-08-14 2008-08-14
US61/088,759 2008-08-14
US9253708P 2008-08-28 2008-08-28
US61/092,537 2008-08-28
PCT/US2008/076806 WO2009039248A2 (en) 2007-09-18 2008-09-18 Methods of treating a flaviviridae family viral infection and compositions for treating a flaviviridae family viral infection

Publications (3)

Publication Number Publication Date
JP2010539241A JP2010539241A (ja) 2010-12-16
JP2010539241A5 true JP2010539241A5 (enExample) 2012-11-08
JP5715820B2 JP5715820B2 (ja) 2015-05-13

Family

ID=40468758

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010525943A Expired - Fee Related JP5715820B2 (ja) 2007-09-18 2008-09-18 フラビウイルス科ファミリーのウイルスへの感染を治療する方法ならびに、フラビウイルス科ファミリーのウイルスへの感染を治療するための組成物

Country Status (8)

Country Link
US (3) US8895598B2 (enExample)
EP (1) EP2203168B1 (enExample)
JP (1) JP5715820B2 (enExample)
CN (1) CN101903026B (enExample)
AR (1) AR066165A1 (enExample)
AU (1) AU2008302295B2 (enExample)
TW (1) TW200927102A (enExample)
WO (2) WO2009039248A2 (enExample)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010107742A2 (en) * 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a flaviviridae family viral infection
EP2203168B1 (en) * 2007-09-18 2014-07-16 Stanford University Compositions for treating a flaviviridae family viral infection
US9101628B2 (en) 2007-09-18 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and composition of treating a flaviviridae family viral infection
US9149463B2 (en) 2007-09-18 2015-10-06 The Board Of Trustees Of The Leland Standford Junior University Methods and compositions of treating a Flaviviridae family viral infection
US8940730B2 (en) 2007-09-18 2015-01-27 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions of treating a Flaviviridae family viral infection
US8975247B2 (en) 2009-03-18 2015-03-10 The Board Of Trustees Of The Leland Stanford Junion University Methods and compositions of treating a flaviviridae family viral infection
WO2010118286A2 (en) * 2009-04-09 2010-10-14 Auspex Pharmaceuticals, Inc. Benzimidazole modulators of h1 receptor and/or ns4b protein activity
WO2010132810A1 (en) * 2009-05-15 2010-11-18 Concert Pharmaceuticals, Inc. Deuterium modified benzimidazoles
RU2407738C1 (ru) * 2009-07-03 2010-12-27 Общество с ограниченной ответственностью "Интеллектуальный Диалог" Противовирусный активный компонент, фармацевтическая композиция, лекарственное средство, способ лечения вирусных заболеваний
US20120232062A1 (en) * 2009-10-20 2012-09-13 Eiger Biopharmaceuticals, Inc. Azaindazoles to treat flaviviridae virus infection
US20110165037A1 (en) * 2010-01-07 2011-07-07 Ismagilov Rustem F Interfaces that eliminate non-specific adsorption, and introduce specific interactions
RU2436786C1 (ru) * 2010-07-23 2011-12-20 Александр Васильевич Иващенко Замещенные индолы, противовирусный активный компонент, способ получения и применения
WO2012096929A2 (en) * 2011-01-11 2012-07-19 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
CN103582632B (zh) 2011-03-31 2015-08-19 拜耳知识产权有限责任公司 取代的苯并咪唑
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
SE1450130A1 (sv) 2011-10-21 2014-05-07 Abbvie Inc Förfaranden för att behandla hcv innefattande minst två direktverkande antivirala agenser, ribavirin men inte interferon
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
EP2583680A3 (en) 2011-10-21 2013-06-12 Abbvie Inc. Mono (PSI-7977) or combination treatment of DAAs for use in treating HCV
MY171759A (en) 2011-12-06 2019-10-28 Univ Leland Stanford Junior Methods and compositions for treating viral diseases
US9550737B2 (en) * 2012-06-11 2017-01-24 Ucb Biopharma Sprl TNF -α modulating benzimidazoles
CN103585616B (zh) * 2013-08-14 2015-05-27 南京工业大学 二肽类似物的用途
EP3636264A1 (en) 2013-08-19 2020-04-15 The Regents of the University of California Compounds and methods for treating an epileptic disorder
WO2015050998A2 (en) 2013-10-01 2015-04-09 The Broad Institute, Inc. Sieve valves, microfluidic circuits, microfluidic devices, kits, and methods for isolating an analyte
HUE059559T2 (hu) 2015-02-25 2022-12-28 Univ California 5HT agonisták az epilepsziás rendellenességek kezelésére
IL310969A (en) 2015-06-30 2024-04-01 Eiger Group Int Inc Use of chloroquine and clemizole compounds for treatment of inflammatory and cancerous conditions
CN109069482B (zh) * 2016-04-01 2022-04-05 杨森制药公司 作为登革热病毒复制抑制剂的经取代的吲哚化合物衍生物
US10653678B2 (en) 2016-04-11 2020-05-19 Genfit Methods of treatment for cholestatic and fibrotic diseases
SG10202004425XA (en) 2016-04-11 2020-06-29 Genfit Methods of treatment for cholestatic and fibrotic diseases
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
WO2018129702A1 (zh) * 2017-01-13 2018-07-19 史仅 蚊虫叮咬瘙痒寨卡等病毒预防医疗器具
CN108096562B (zh) * 2017-12-25 2021-05-11 武汉百药联科科技有限公司 20s蛋白酶体抑制剂在制备治疗日本乙型脑炎病毒感染的药物中的用途
WO2019126860A1 (pt) * 2017-12-29 2019-07-04 Instituto Butantan Composição farmacêutica para o tratamento de infecção causada por vírus da família flaviviridae, e, uso da composição
CN108660253B (zh) * 2018-04-17 2022-05-31 广东省妇幼保健院（广东省妇产医院、广东省儿童医院） 一种基于悬浮微珠阵列系统检测虫媒介病毒的探针、引物、检测试剂盒及检测方法
CN109020895B (zh) * 2018-08-07 2020-04-24 枣庄学院 一种金属催化的1-苄胺基取代苯并咪唑的合成方法
HUE066335T2 (hu) 2018-10-05 2024-07-28 Annapurna Bio Inc Vegyületek és készítmények APJ receptor aktivitáshoz kapcsolódó állapotok kezelésére
WO2020210373A1 (en) * 2019-04-09 2020-10-15 Tremeau Pharmaceuticals, Inc. Treatment of viral hemorrhagic fevers with etoricoxib
CN214973877U (zh) 2019-08-09 2021-12-03 胡桃钳医疗公司 用于形成治疗性多核苷酸的微流体设备及微流体路径装置
CN115884770B (zh) * 2020-03-09 2025-03-18 南京强新生物医药有限公司 治疗冠状病毒感染的联用药物及治疗方法
CN111393372B (zh) * 2020-05-12 2022-08-26 中国药科大学 一种苯并咪唑衍生物及其制备方法和用途
US12274700B1 (en) 2020-10-30 2025-04-15 Accencio LLC Methods of treating symptoms of coronavirus infection with RNA polymerase inhibitors
EP4376808A1 (en) * 2021-07-30 2024-06-05 Epygenix Therapeutics, Inc. Clemizole formulation
JP2025518536A (ja) * 2022-05-20 2025-06-17 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー 脂肪肝及びウイルス感染症を治療するための方法及び組成物
CN119707828B (zh) * 2024-12-18 2025-12-05 江苏天和制药股份有限公司 一种盐酸克立咪唑的合成方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2689853A (en) * 1954-09-21 Certain i
US2684327A (en) 1951-11-02 1954-07-20 United Chromium Inc Bright nickel plating
GB1045534A (en) 1963-02-09 1966-10-12 Schering Ag New 1-benzyl-5,6-dialkoxy benzimidazoles and a process for their manufacture
DE1620450C3 (de) 1964-07-23 1976-01-02 Schering Ag, 1000 Berlin Und 4619 Bergkamen 1 - (2- Hydroxybenzyl) -2-piperazinomethylbenzimidazole, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US3428634A (en) 1965-03-13 1969-02-18 Acraf 3-tertiary amino alkoxy-1-hydrocarbon indazoles
DE2436883C2 (de) 1974-07-29 1985-08-22 Schering AG, 1000 Berlin und 4709 Bergkamen Benzimidazol-Derivate, Verfahren zu ihrer Herstellung und diese enthaltende Arzneimittel
US4269835A (en) 1979-12-13 1981-05-26 Whittle Barry J Nasal composition for relieving nasal distress
US5552426A (en) 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide
CZ104795A3 (en) 1994-04-29 1996-02-14 Lilly Co Eli Benzimidazole derivative, process of its preparation, its use for preparing a pharmaceutical preparation and the pharmaceutical composition containing thereof
CA2281927C (en) * 1997-02-25 2004-01-27 Christopher J. Michejda Substituted benzimidazoles as non-nucleoside inhibitors of reverse transcriptase
US6211177B1 (en) 1998-11-24 2001-04-03 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted 2-aryl-benzimidazole derivatives
US6770666B2 (en) * 1999-12-27 2004-08-03 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
US6476062B2 (en) 2000-03-30 2002-11-05 Schering Corporation Chemokine receptor antagonists
US6448281B1 (en) 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP1322325A4 (en) 2000-07-20 2004-09-15 Merck & Co Inc INHIBITION OF PROCESSING AND REPLICATION OF HEPATITIS C VIRUS
EP1392290B1 (en) 2001-03-22 2005-05-18 Ucb, S.A. Use of certain substituted pyrrolidones such as piracetam in the treatment of viral and other diseases
AR035543A1 (es) * 2001-06-26 2004-06-16 Japan Tobacco Inc Agente terapeutico para la hepatitis c que comprende un compuesto de anillo condensado, compuesto de anillo condensado, composicion farmaceutica que lo comprende, compuestos de benzimidazol, tiazol y bifenilo utiles como intermediarios para producir dichos compuestos, uso del compuesto de anillo con
US7160879B2 (en) 2002-01-10 2007-01-09 Neurogen Corporation Melanin concentrating hormone receptor ligands: substituted 2-(4-benzyl-piperazin-1-ylmethyl)- and 2-(4-benzyl-diazepan-1-ylmethyl)-1H-benzoimidazole analogues
JP2006517969A (ja) 2003-02-14 2006-08-03 コンビナトアールエックス インコーポレーティッド 免疫炎症性障害の治療のための組み合わせ療法
HRP20090487T1 (hr) 2003-04-07 2009-12-31 Pharmacyclics Hidroksamati kao terapeutski agensi
BRPI0413234A (pt) 2003-08-01 2006-10-03 Genelabs Tech Inc derivados de imidazola bicìclica contra flaviviridae
US7582428B2 (en) * 2003-08-22 2009-09-01 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for identifying anti-HCV agents
US20050192261A1 (en) 2003-09-15 2005-09-01 Jost-Price Edward R. Methods and reagents for the treatment of immunoinflammatory disorders
EP1686949A2 (en) * 2003-11-24 2006-08-09 Viropharma Incorporated Compounds, compositions and methods for treatment and prophylaxis of hepatitis c viral infections and associated diseases
RU2006134022A (ru) 2004-02-27 2008-04-10 Ф.Хоффманн-Ля Рош Аг (Ch) Производные индазола и содержащие их фармацевтические композиции
CN101027303A (zh) * 2004-07-27 2007-08-29 吉里德科学公司 咪唑并[4，5－d]嘧啶类、其应用和制备方法
GB0416728D0 (en) 2004-07-27 2004-09-01 7Tm Pharma As Medicinal use of receptor ligands
WO2006135383A2 (en) 2004-08-04 2006-12-21 Myriad Genetics, Inc. Indazoles
EP1888033B1 (en) * 2005-06-09 2014-02-19 Meda AB Method and composition for treating inflammatory disorders
EP1988776B1 (en) 2006-03-02 2012-08-08 Siga Technologies, Inc. Antiviral drugs for treatment of arenavirus infection
CN101437519A (zh) 2006-03-31 2009-05-20 艾博特公司 吲唑化合物
BRPI0711040A2 (pt) 2006-03-31 2011-08-23 Astrazeneca Ab uso de um composto, método para o tratamento ou prevenção de distúrbios, composto, e, composição farmacêutica
US20080161324A1 (en) * 2006-09-14 2008-07-03 Johansen Lisa M Compositions and methods for treatment of viral diseases
DE102007028521A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh Indazolamidderivate
EP2203168B1 (en) 2007-09-18 2014-07-16 Stanford University Compositions for treating a flaviviridae family viral infection
US9101628B2 (en) 2007-09-18 2015-08-11 The Board Of Trustees Of The Leland Stanford Junior University Methods and composition of treating a flaviviridae family viral infection

Similar Documents

Publication Publication Date Title
JP2010539241A5 (enExample)
JP2011521903A5 (enExample)
JP2011518835A5 (enExample)
CA2490200A1 (en) 2' and 3'-nucleoside prodrugs for treating flaviviridae infections
RU2483073C2 (ru) Фосфадиазиновые ингибиторы iv полимеразы hcv
AR066165A1 (es) Metodos de tratamiento de una infeccion viral de la familia flaviviridae, composiciones para el tratamiento de una infeccion viral de la familia flaviviridae y ensayos de control para identificar composiciones para el tratamiento de una infeccion viral de la familia flaviviridae
JP2014514308A5 (enExample)
ES2671478T3 (es) Derivados de 2'-etinil nucleósidos para el tratamiento de infecciones virales
ES2680550T3 (es) Combinaciones de inhibidores del virus de la hepatitis C
RU2011133741A (ru) Модифицированные 2'- и 3'-нуклеозиды и их применение для получения лекарственного средства для лечения инфекций flaviviridae
JP2012504126A5 (enExample)
JP2005524632A5 (enExample)
JP2008518943A5 (enExample)
JP2016518359A5 (enExample)
JP2013521279A5 (enExample)
JP2013517286A5 (enExample)
JP2015525220A5 (enExample)
JP2012519691A5 (enExample)
JP2014503516A5 (enExample)
HRP20140219T1 (hr) Analozi karba-nukleozida za antivirusno lijeäśenje
JP2010532352A5 (enExample)
JP2012504632A5 (enExample)
JP2012513479A5 (enExample)
JP2011511841A5 (enExample)
JP2011528713A5 (enExample)